Perceptions about respiratory syncytial virus (RSV) and attitudes toward the RSV vaccine among the general public in China: A cross-sectional survey.

Qiang Wang, Shixin Xiu, Liuqing Yang, Lan Li, Min Yang, Xuwen Wang, Yuan Shen, Weibing Wang, Leesa Lin
Author Information
  1. Qiang Wang: Department of Epidemiology, School of Public Health, Fudan University, Shanghai, China.
  2. Shixin Xiu: Department of Immunization, Wuxi Center for Disease Control and Prevention, Wuxi, China.
  3. Liuqing Yang: Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing, China.
  4. Lan Li: Centre for Digital Public Health in Emergencies, Institute for Risk and Disaster Reduction, University College London, London, UK.
  5. Min Yang: Department of Immunization, Wuxi Center for Disease Control and Prevention, Wuxi, China.
  6. Xuwen Wang: Department of Immunization, Wuxi Center for Disease Control and Prevention, Wuxi, China.
  7. Yuan Shen: Department of Immunization, Wuxi Center for Disease Control and Prevention, Wuxi, China.
  8. Weibing Wang: Department of Epidemiology, School of Public Health, Fudan University, Shanghai, China.
  9. Leesa Lin: Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.

Abstract

Our study aims to assess the public's perceptions of respiratory syncytial virus (RSV) and attitudes toward the RSV vaccine and to identify associated factors in China. A nationwide cross-sectional survey conducted using an online platform between August 16 and September 14, 2023. Questions related to socio-demographics, awareness, knowledge, perceptions of susceptibility and severity of RSV, and attitudes toward the RSV vaccine were included in the questionnaire. We used the chi-square test and logistic regression model to explore the associated factors. Overall, 2133 individuals were included in this study. Nearly a quarter of participants (24.3%) indicated that they had never heard of RSV. The proportion of individuals aged over 50 years reporting never having heard of RSV (36.5%) and having a low knowledge level of RSV (55.3%) was significantly higher that of other younger age groups. More than half of individuals (55.7%) exhibited low level of perceptions of susceptibility concerning RSV infection. A total of 68.4% of the participants expressed willingness to receive the RSV vaccine. Younger age was positively associated with a higher willingness to be vaccinated. The most frequent reason for declining the vaccine was "Concern about vaccine's safety or side effects." About 60% of individuals considered a price of RSV vaccine below 200 CNY (28 USD) as acceptable. The awareness and perceived susceptibility to RSV infection were limited to the Chinese public. It is necessary to take measures to address the low awareness and knowledge of RSV and acceptability of the RSV vaccine among older adults.

Keywords

References

  1. Pediatr Infect Dis J. 2019 Sep;38(9):944-951 [PMID: 31261362]
  2. J Infect Dis. 2022 Aug 12;226(Suppl 1):S102-S109 [PMID: 34522947]
  3. Prev Med. 2021 Sep;150:106694 [PMID: 34171345]
  4. Nat Med. 2021 Feb;27(2):225-228 [PMID: 33082575]
  5. Vaccines (Basel). 2023 Aug 19;11(8): [PMID: 37631954]
  6. Influenza Other Respir Viruses. 2023 Jan;17(1):e13031 [PMID: 36369772]
  7. J Med Internet Res. 2004 Sep 29;6(3):e34 [PMID: 15471760]
  8. Lancet. 2020 Sep 26;396(10255):898-908 [PMID: 32919524]
  9. N Engl J Med. 2022 Jun 23;386(25):2377-2386 [PMID: 35731653]
  10. Vaccines (Basel). 2022 Jul 13;10(7): [PMID: 35891283]
  11. Vaccine X. 2023 May 12;14:100314 [PMID: 37234596]
  12. JMIR Form Res. 2023 Feb 7;7:e39994 [PMID: 36693149]
  13. Expert Rev Vaccines. 2022 Oct;21(10):1523-1531 [PMID: 35929971]
  14. Vaccine. 2019 Jan 21;37(4):565-570 [PMID: 30598385]
  15. Lancet. 2022 May 28;399(10340):2047-2064 [PMID: 35598608]
  16. Nat Med. 2023 Mar;29(3):623-631 [PMID: 36720270]
  17. MMWR Morb Mortal Wkly Rep. 2023 Jul 21;72(29):793-801 [PMID: 37471262]
  18. Curr Opin Infect Dis. 2023 Oct 1;36(5):379-384 [PMID: 37610444]
  19. Vaccine. 2018 May 3;36(19):2673-2682 [PMID: 29606516]
  20. N Engl J Med. 2023 Apr 20;388(16):1451-1464 [PMID: 37018474]
  21. Pediatr Rep. 2022 Mar 24;14(2):147-165 [PMID: 35466200]
  22. J Infect Public Health. 2023 Feb;16(2):163-170 [PMID: 36535136]

MeSH Term

Humans
Middle Aged
Aged
Respiratory Syncytial Virus Infections
Cross-Sectional Studies
Respiratory Syncytial Virus Vaccines
Vaccination
Respiratory Syncytial Virus, Human
China
Antibodies, Viral

Chemicals

Respiratory Syncytial Virus Vaccines
Antibodies, Viral

Word Cloud

Created with Highcharts 10.0.0RSVvaccineperceptionsindividualssyncytialvirusattitudestowardassociatedawarenessknowledgesusceptibilitylowstudyrespiratoryfactorsChinacross-sectionalsurveyincludedparticipants3%neverheardlevel55higherageinfectionwillingnesspublicamongaimsassesspublic'sidentifynationwideconductedusingonlineplatformAugust16September142023Questionsrelatedsocio-demographicsseverityquestionnaireusedchi-squaretestlogisticregressionmodelexploreOverall2133Nearlyquarter24indicatedproportionaged50 yearsreporting365%significantlyyoungergroupshalf7%exhibitedconcerningtotal684%expressedreceiveYoungerpositivelyvaccinatedfrequentreasondeclining"Concernvaccine'ssafetysideeffects"60%consideredprice200CNY28USDacceptableperceivedlimitedChinesenecessarytakemeasuresaddressacceptabilityolderadultsPerceptionsgeneralChina:Respiratory

Similar Articles

Cited By (4)